Zenith Drugs Limited (NSEI: ZENITHDRUG)
Health Care · Pharmaceuticals · IN
Rs44.65
+6.31% today · -29.1% 1Y
Zenith Drugs Limited (NSEI: ZENITHDRUG) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $8.01M and employs 182 people.
Over the last twelve months the share price has lost 29.1%, trading between 33.30 and 76.00.
Tweenvest scores Zenith Drugs Limited across four factors: quality 54/100, value 40/100, growth 45/100. Its strongest factor is quality.
ZENITHDRUG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.01M
- Revenue (TTM)
- $18.26M
- P/E
- 19.41
- EPS
- 2.30
- Dividend yield
- —
- Beta (5Y)
- 1.42
- 52-week high
- Rs76.00
- 52-week low
- Rs33.30
- Avg volume (3M)
- —
- Shares outstanding
- 17.15M
- Employees
- 182
- Next earnings
- —
About Zenith Drugs Limited
Zenith Drugs Ltd. engages in the manufacture and trade of medicines. It offers a wide range of formulations in various forms such as ORS powder, liquid orals, ointments, liquid externals, and capsules. The company was founded by Shri Ramniklal T. Soni and Mr. Mukesh Jain on November 15, 2000 and is headquartered in Indore, India.
- ISIN
- INE0QWN01013
- Founded
- 1956
- Listed since
- Feb 27, 2024
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.